Halobetasol / tazarotene Topical Product
RxNorm 2166086

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2166086 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: halobetasol / tazarotene Topical Product.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDG
Halobetasol / tazarotene Topical Product
AUI:11349580
View
PT
Halobetasol- and tazarotene-containing product in cutaneous dose form
AUI:11825302
View
FN
Product containing halobetasol and tazarotene in cutaneous dose form (medicinal product form)
AUI:11438458
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDGPrescribable

Semantic Clinical Dose Form Group (SCDG):
Halobetasol / tazarotene Topical Product
(Atom ID: 11349580)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
halobetasol / tazarotene Topical Product
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2166086
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11349580
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDG
Semantic Clinical Dose Form Group (Ingredient + Dose Form Group)
Source Code
2166086
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AVAILABLE STRENGTH
0.1 MG/ML (expressed as halobetasol propionate) / 0.45 MG/ML
Available drug strengths listed in the order of ingredients from the drug
PTPrescribable

Designated preferred name (PT):
Halobetasol- and tazarotene-containing product in cutaneous dose form
(Atom ID: 11825302)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Halobetasol- and tazarotene-containing product in cutaneous dose form
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2166086
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11825302
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
787753009
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
FNPrescribable

Full form of descriptor (FN):
Product containing halobetasol and tazarotene in cutaneous dose form (medicinal product form)
(Atom ID: 11438458)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Product containing halobetasol and tazarotene in cutaneous dose form (medicinal product form)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2166086
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11438458
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
787753009
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.